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Results Four metabolites were significantly associated 
with milk intake in the TwinsUK cohort after adjustment 
for multiple testing (P < 8.08 × 10−5) and covariates (BMI, 
age, batch effects, family relatedness and dietary covari-
ates) and replicated in the independent cohorts. Among the 
metabolites identified, the carnitine metabolite trimethyl-N-
aminovalerate (β = 0.012, SE = 0.002, P = 2.98 × 10−12) 
and the nucleotide uridine (β = 0.004, SE = 0.001, 
P = 9.86 × 10−6) were the strongest novel predictive 
biomarkers from the non-targeted platform. Notably, the 
association between trimethyl-N-aminovalerate and milk 
intake was significant in a group of MZ twins discordant 
for milk intake (β = 0.050, SE = 0.015, P = 7.53 × 10−4) 
and validated in the urine of 236 UK twins (β = 0.091, 
SE = 0.032, P = 0.004). Two metabolites from the tar-
geted platform, hydroxysphingomyelin C14:1 (β = 0.034, 
SE = 0.005, P = 9.75 × 10−14) and diacylphosphatidyl-
choline C28:1 (β = 0.034, SE = 0.004, P = 4.53 × 10−16), 
were also replicated.
Abstract 
Purpose Milk provides a significant source of calcium, 
protein, vitamins and other minerals to Western populations 
throughout life. Due to its widespread use, the metabolic 
and health impact of milk consumption warrants further 
investigation and biomarkers would aid epidemiological 
studies.
Methods Milk intake assessed by a validated food fre-
quency questionnaire was analyzed against fasting blood 
metabolomic profiles from two metabolomic platforms 
in females from the TwinsUK cohort (n = 3559). The top 
metabolites were then replicated in two independent popu-
lations (EGCUT, n = 1109 and KORA, n = 1593), and the 
results from all cohorts were meta-analyzed.
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Conclusions We identified and replicated in independ-
ent populations four novel biomarkers of milk intake: 
trimethyl-N-aminovalerate, uridine, hydroxysphingomy-
elin C14:1 and diacylphosphatidylcholine C28:1. Together, 
these metabolites have potential to objectively examine and 
refine milk-disease associations.
Keywords Nutrition · Metabolomics · Twins · 
Biomarkers · Milk
Abbreviations
DZ  Dizygotic
EGCUT  Estonian Genome Center of the Univer-
sity of Tartu
KORA  Cooperative Health Research in the 
Region of Augsburg
PC aa C28:1  Diacylphosphatidylcholine C28:1
MZ  Monozygotic
SM(OH) C14:1  Hydroxysphingomyelin C14:1
Introduction
Milk and dairy products have been consumed throughout 
life by lactase-producing cultures for thousands of years, 
aided by the lactase persistence/dairying co-evolution esti-
mated to have occurred 7500 years ago [1]. They provide 
excellent sources of calcium and other micronutrients for 
many populations around the world [2]. Studies of the 
long-term health and metabolic implications of dairy prod-
uct consumption based on recall have, however, yielded 
inconsistencies [3]. Epidemiological studies have mainly 
explored relationships with combined dairy product intake, 
though different products may promote different physi-
ological effects, which may be due to varying macronutri-
ent contents (reduced lactose and whey fraction), micro-
biological species (and their metabolic products) or altered 
nutrient absorption as a result of processing [3]. Of all 
dairy products, fluid milk is consumed the most frequently 
in many Western countries though consumption has been 
declining in some, such as the USA [4] and UK [5] likely 
due to health concerns about fat. Milk consumption is gen-
erally encouraged throughout life, for the growth of strong 
bones and teeth during childhood through to aging women 
for the prevention of osteoporosis and fractures [6]. The 
evidence for the long-term consumption of milk on health 
outcomes from observational studies has been somewhat 
inconsistent, with a meta-analysis of 17 prospective studies 
suggestive of a protective effect on CVD and no relation-
ship with mortality [7], while two large Swedish cohorts 
identified associations with mortality [8]. Usage of dif-
ferent questionnaires to measure milk intake as well as 
recall bias complicates large population comparisons; thus, 
incorporation of objective biomarkers into epidemiological 
methods is essential.
Metabolomics provides a snapshot of the metabolic sta-
tus of an individual by high-throughput measurement of 
small metabolites and has the potential to refine diet–dis-
ease associations, primarily through food biomarker iden-
tification and providing insight into novel nutrient and 
disease pathways [9]. A recent example involved using 
metabolites of alcohol to predict indices of cardiovascular 
health [10]. A limiting factor in many metabolomic stud-
ies is the amount of inter-individual variation in metabolite 
levels, up to 81 % of which is attributable to genetics [11]. 
Monozygotic (MZ) twins, matched for baseline genet-
ics, age, sex and early life experiences, and discordant for 
dietary phenotypes, provide a natural case–control experi-
ment to evaluate diet-metabolite associations while control-
ling for these factors [12]. In this study, we present a novel 
multi-platform targeted and non-targeted metabolomics 
analysis of milk consumption to identify potential biomark-
ers of long-term milk intake, with our main findings repli-
cated in two European populations.
Subjects and material
A pipeline of the study design is presented in Fig. 1.
Discovery sample
Subjects included in the analysis were twins enrolled in the 
TwinsUK registry, a national register of UK adult female 
twins [13]. Healthy twins were recruited nation-wide pri-
marily through media campaigns without selecting for par-
ticular diseases or traits. In this study, we included 3559 
female twins, who completed at least one 131-item FFQ 
between 1995 and 2007, and had metabolomics and BMI 
data available within 5 years of FFQ completion. The 131-
item Food Frequency Questionnaire (FFQ) was developed 
and validated against pre-established nutrient biomarkers 
for the European Prospective Investigation into Diet and 
Cancer (EPIC) Norfolk [14]. Quality control, subject exclu-
sion criteria and methods for nutrient determination from 
FFQ data has been previously described [15]. Briefly, sub-
mitted FFQs were excluded if greater than 10 food items 
were left unanswered, or if the total energy intake estimate 
derived from FFQ as a ratio of the subject’s estimated basal 
metabolic rate (determined by the Harris–Benedict equa-
tion [16] was more than two standard deviations outside the 
mean of this ratio (<0.52 or >2.58). Milk intake was rep-
resented in servings per week with one serving equal to 1 
pint (585 g). To determine intakes, participants were asked 
which type of milk they most often used and how much 
milk they consumed per day: none, ¼ pint (146.25 g), ½ 
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pint (292.5 g), ¾ pint (438.75), 1 pint (585 g) or more than 
one pint (this was coded as 1½ pints and equal to 877.5 g). 
Intake frequencies of all milk types from dairy sources 
(prepared dried, whole, semi-skimmed, and skimmed 
cow’s milk) were summed, and the variable adjusted for 
total reported energy intake using the residual method 
[17]. For other dairy variables, intakes of average serving 
sizes were assessed on a 9-point scale (ranging from never 
or less than once per month to 6+ times per day) and fre-
quencies summed into the following broader categories: 
yoghurt (full fat and low fat), cheese [cottage cheese and 
dairy cheese (for example, cheddar, brie, edam)], dairy des-
serts (for example, chocolate mousse, cream caramels), 
ice cream, creams [single (sour cream) and double (clot-
ted cream)], and butter. Other phenotypic data relevant to 
the present study include BMI and zygosity (determined by 
methods outlined previously [13]). The study was approved 
by the St. Thomas’ Hospital Research Ethics committee 
and all subjects provided informed written consent.
Replication cohorts
EGCUT The Estonian Biobank is the population-based 
biobank of the Estonian Genome Center of the University 
of Tartu (EGCUT) [18]. All subjects are unrelated volun-
teers and were recruited randomly by general practitioners 
(GP) and physicians in hospitals. For this analysis, subjects 
with milk intake and fasted serum metabolomics measure-
ments, as determined by the targeted mass spectrometry-
based Biocrates platform (Biocrates AbsoluteIDQ p150 Kit; 
www.biocrates.com), were used (n = 1109). All subjects 
responded to the following question as part of the general 
questionnaire: “Last week on how many days did you con-
sume milk products?” The response was recorded on a four 
point scale: (1) never, (2) once or twice, (3) 3–5 times, (4) 
6–7 times. The questionnaire was administered on the same 
day (during the same visit) as the blood sample was drawn.
KORA The Cooperative Health Research in the Region 
of Augsburg (KORA) study includes unrelated individu-
als from the general population in the region of Augsburg, 
Germany [19]. As part of the fourth survey (S4), a total of 
4261 persons aged 25–74 years were examined between 
1999 and 2001. For the present analysis, 1593 individuals 
with serum levels of the significant metabolites associated 
with milk intake identified in TwinsUK by the non-targeted 
Metabolon and targeted Biocrates platforms and informa-
tion on milk intake were used. Dietary intake was assessed 
Fig. 1  Pipeline of study design
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using a validated FFQ as part of a standardized interview at 
the same day blood samples for measurement of metabolites 
was taken [20]. The FFQ consisted of 24 food items and 
asked subjects to recall their “average intake” without speci-
fying a time frame in the following six frequency categories: 
almost daily, several times per week, about once a week, 
several times per month, once a month or less, never. The 
food item “milk intake including buttermilk” was used in 
the present analysis. Prior to analysis, the milk intake vari-
able was recoded for ease of interpretation so that the least 
frequency (never) was coded as 1 and the highest frequency 
(almost daily) was coded as 6, and the rest of the categories 
changed accordingly (once a month or less, 2; several times 
per month, 3; about once a week, 4; and several times per 
week, 5).
Metabolomic profiling
Following six or more hours of fasting, blood samples were 
taken. The samples were frozen at −45 °C until metabo-
lomics profiling, further details on sample protocols can be 
found in Supplementary text 1.
Metabolon
Non-targeted mass spectroscopy-based metabolomic profil-
ing was conducted by the metabolomics provider Metabo-
lon, Inc. (Durham, NC) on 3559 fasting blood samples and 
236 spot urine samples taken at the same time as plasma 
from TwinsUK, as previously described [21, 22]. The 
Metabolon platform includes 280 structurally named bio-
chemicals (known metabolites) categorized into the follow-
ing broad categories: amino acids, carbohydrates, vitamins, 
lipids, nucleotides, peptides, and xenobiotics. An asterisk 
(*) at the end of the metabolite name indicates the metabo-
lite identity has not been confirmed by accurate mass data. 
Further details on the handling of instrumental variability 
can be found in Supplementary text 1.
Biocrates
A targeted metabolomic assay was also performed in a 
subset of 858 participants, with samples overlapping with 
Metabolon profiling, in the TwinsUK study using the Bio-
crates Absolute IDQ™-kit p150 (BIOCRATES Life Sci-
ences, AG, Innsbruck, Austria) as previously described 
[23, 24]. Briefly, the flow injection analysis (FIA) tandem 
mass spectrometry (MS/MS) method is used to quantify 
163 known small molecule metabolites simultaneously by 
multiple reaction monitoring. Quantification of the metabo-
lites is then achieved by reference to appropriate internal 
standards.
The Biocrates dataset contains acylcarnitines (Cx:y), 
hydroxylacylcarnitines [C(OH)x:y] and dicarboxylacylcar-
nitines (Cx:y-DC); amino acids; sphingomyelins (SMx:y) 
and sphingomyelin-derivatives [SM(OH)x:y]; and glycer-
ophospholipids (PC).
The Biocrates platform measures absolute metabolite 
value (mM).
Quality control of the metabolomic dataset
Metabolon Quality control on the metabolomics dataset 
was performed as previously described [21, 22]. Briefly, 
raw data were median-normalized by dividing metabolite 
concentrations by the day median of that metabolite and 
then inverse-normalized. Thus, in the case where instru-
ment instability was not caught, the impact would be lim-
ited to a given batch of samples within the study. Metabo-
lites with more than 20 % of values missing were excluded 
to avoid false-positive associations. Minimum run day 
measures were imputed to the missing values.
Biocrates The metabolite serum concentrations were log 
transformed as these were right-skewed.
Statistical analysis
Statistical analysis was carried out using Stata version 12.
For each metabolite, random intercept linear regres-
sion analysis was first undertaken in the TwinsUK sample 
adjusting for age, metabolite batch, BMI, family related-
ness and potential dietary confounders:
where Yi is the metabolite and Xij the dietary phenotype of 
twin j from pair i, ζj, is the family-specific error compo-
nent that captures the unobserved heterogeneity or fam-
ily characteristics. Dietary confounders were identified by 
using a backward stepwise regression model including a 
set of dietary phenotypes (food group, alcohol and unsatu-
rated fat [to account for oil consumption]) intakes that were 
significantly associated with milk intake using a cut-off 
threshold P < 0.001. We adjusted for multiple testing using 
Bonferroni correction thus giving a significant threshold of 
8.08 × 10−5 (0.05/(619 detected metabolites)).
We replicated each significant milk-metabolite associa-
tion in the two independent cohorts, KORA and EGCUT, 
using linear regression adjusting for age, sex, BMI and 
fasted status (only in KORA). We then combined the results 
using inverse variance fixed-effects meta-analysis. Associa-
tions that passed the Bonferroni cut-off for multiple testing 
(P < 8.08 × 10−5) were considered replicated.
For the top replicated metabolite from TwinsUK, the 
same linear regression analysis (though not adjusted for 
Υi = β0 + βiXij + γiageij + δiBMIij + ζj + εij
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dietary covariates) was undertaken in a sample of MZ twin 
pairs for milk intake (twin pairs at least one SD apart in 
milk intake). The MZ discordant twin pair design provides 
a powerful means to examine associations while control-
ling for age, sex and baseline genetic sequence. Associa-
tions between the replicated milk-associated blood metabo-
lite from TwinsUK with intakes of other dairy products in 
the whole TwinsUK population were determined using the 
same linear regression model described above, though not 
adjusted for dietary confounders.
The beta coefficients presented in the results of each lin-
ear regression analysis represent the amount of milk con-
sumed that corresponds to a 1 SD increase in the metabo-
lite level.
Binary classification tests
The replicated metabolites (adjusted for covariates) were 
fitted into a logistic regression models each with the lower 
quintile of milk intake assigned a negative outcome (0) and 
the top (high intake) quintile of milk intake was consid-
ered a positive outcome (1). A binary classification test was 
then conducted to evaluate the utility of the metabolites. 
The ability of the metabolites to correctly classify sub-
jects consuming a high serving of milk per day (sensitivity; 
true positive rate) and correctly classify subjects consum-
ing the lower quintile of servings of milk per day (speci-
ficity; false-positive rate) of the model was predicted, and 
the receiver operating characteristic curve (ROC) was gen-
erated by plotting the true positive rate against the false-
positive rate at multiple threshold settings. We further com-
pared the models for replicated metabolites against dairy 
fat biomarkers pentadecanoic (C15:0) and heptadecanoic 
acid (C17:0) (recently confirmed by a dietary interven-
tion study [25]) by testing the equality of the ROC area for 
each.
A second binary classification test was performed to 
assess the utility of the replicated metabolites to predict 
genotypic lactase persistence (positive outcome, 1) ver-
sus non (negative outcome, 0). The replicated metabolites 
(adjusted for covariates), reported milk intake, lactose 
intake and blood levels of dairy fat biomarkers (adjusted 
for covariates), were each fitted into a logistic regression 
model to classify lactase persistent individuals versus non-
persistent according to genotype (SNP rs4988235 on the 
MCM6 gene: CC, lactase non-persistent; TT or CT lactase 
persistent). The ability of the replicated metabolites, milk 
fat biomarkers, and reported lactose and milk intakes to 
correctly classify lactase persistent subjects (sensitivity; 
true positive rate) and correctly classify lactase non-persis-
tent subjects (specificity; false-positive rate) of the model 
were predicted and the receiver operating characteristic 
curves (ROC) produced. The equality of the ROC area for 
each model was tested against the ROC area for the repli-
cated metabolites.
Results
The demographic characteristics of the study populations 
are presented in Table 1. The TwinsUK sample was an 
all-female population on the upper end of middle age, the 
KORA sample was older and EGCUT younger and both 
had an approximately even sex ratio. Average BMI for 
all groups was in the overweight classification (>25 kg/
m2). Total nutrient intakes for TwinsUK are represented 
as a percentage of UK recommended intakes by tertile of 
milk intake (Fig. 2). For subjects consuming the top ter-
tile of milk (mean weekly servings: 6.07, SD = 1.70), 
milk intake contributed to, or nearly, 100 % of the rec-
ommended intakes of vitamin B12 (191 %), riboflavin 
(110 %), iodine (110 %), calcium (91 %) and phospho-
rous (90 %). The corresponding increases in nutrient 
profiles were seen for increasing tertiles of milk intake 
(P < 0.001). In the same group (P < 0.001), decreases 
in non-milk specific nutrients, vitamin C, carotene, vita-
min E, MUFA, PUFA, non-starch polysaccharide (NSP) 
and alcohol were observed; therefore, intakes of relevant 
foods and nutrients were accounted for in the subsequent 
metabolomic analysis.
Metabolites associated with milk consumption
A total of nine metabolites passed the Bonferroni cutoff for 
association (P < 8.08 × 10−5) from the targeted (Biocrates) 
and non-targeted (Metabolon) panels in the TwinsUK pop-
ulation (Table 2). To ensure genetic relatedness of the twin 
pairs did not influence our results, we ran the same linear 
regression analysis including zygosity as a covariate and 
our results were unchanged.
Table 1  Characteristics of the participants by study group
Characteristics are expressed in mean (SD) for age, BMI and milk 
intake and the male to female ratio (M:F) for sex
a Milk intake is expressed in servings per week for TwinsUK, the 
average frequency category of milk intake for KORA (never, 1; once 
a month or less, 2; several times per month, 3; about once a week, 4; 
several times per week, 5; almost daily, 6), and the number of days 
per week on which milk products were consumed for EGCUT
TwinsUK KORA EGCUT
(n = 3559) (n = 1593) (n = 1109)
Age (years) 55.3 (13.4) 64.1 (5.5) 37.9 (15.7)
BMI (kg/m2) 26.0 (4.9) 28.5 (4.3) 25.2 (4.6)
M:F 0:3559 824:769 555:554
Milk intakea 3.6 (2.2) 3.5 (2.0) 3.5 (0.7)
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Targeted metabolomics
The glycerophospholipid diacylphosphatidylcholine C28:1 
(PC aa C28:1; β = 0.024, SE = 0.005, P = 7.24 × 10−7) 
and the sphingolipid hydroxysphingomyelin C14:1 
(SM(OH) C14:1; β = 0.024, SE = 0.005, P = 1.42 × 10−7) 
from the Biocrates platform were significantly associated 
with milk intake in TwinsUK and were replicated both in 
EGCUT and KORA (meta-analysis results: PC aa C28:1 
(β = 0.034, SE = 0.004, P = 4.53 × 10−16) and SM(OH) 
C14:1 (β = 0.034, SE = 0.005, P = 9.75 × 10−14)). See 
Table 2.
Non‑targeted metabolomics
Seven known non-targeted metabolites were significantly 
associated with milk intake in TwinsUK and two were also 
independently replicated in KORA (meta-analysis results: 
trimethyl-N-aminovalerate (β = 0.012, SE = 0.002, 
P = 2.98 × 10−12) and uridine (β = 0.004, SE = 0.001, 
P = 9.86 × 10−6)). We find a consistent and statistically 
significant association of trimethyl-N-aminovalerate and 
milk intake in a subpopulation of 484 MZ twins discordant 
for milk intake (β = 0.050, SE = 0.015, P = 7.53 × 10−4) 
(Fig. 3).
Fig. 2  Total nutrient intakes for TwinsUK represented as a percent-
age of UK recommended intakes by tertile of milk intake. Total nutri-
ent intakes for TwinsUK represented as a percentage of UK recom-
mended intakes by tertile of milk intake. Average nutrient intakes 
by increasing tertile of milk intake from clockwise (lightest to dark-
est) were assessed for percentage of the recommended intakes for 
55-year-old women (according to the UK Dietary Reference Values 
[47]). The blue color represents the amount milk consumption con-
tributes to the intake of each nutrient. Using milk intake by tertile 
as the predictor of the residual energy adjusted nutrient intakes in 
a linear regression statistically significant trends (P < 0.001) were 
observed for all nutrients, except cholesterol, sodium, retinol, vitamin 
D, niacin and folate. Carotene and retinol are represented as percent-
age of the recommended intake for total retinol equivalents. There 
is no UK DRV for vitamin D; therefore, 10 ug/d was used. Mean 
weekly residual-adjusted milk servings by tertile (grams per day in 
parentheses): tertile 1, mean[SD] = 1.27[1.04] (111.5[80.7]); ter-
tile 2, 3.48[0.50] (295.2[35.2]); tertile 3, 6.07[1.70] (507.0[131.9]). 
Trans, trans fatty acids; NSP non-starch polysaccharides
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Associations between replicated metabolites and dairy 
product intakes
Replicated metabolites were further examined for their 
specificity to measure milk intake in TwinsUK. To sepa-
rate milk or general dairy product intake, we repeated the 
analysis against weekly servings of other dairy products 
in the whole TwinUK sample (i.e., yoghurt, cheese, dairy 
desserts, ice cream, creams and butter; Supplementary 
Table S1). The association with total dairy product intake 
and trimethyl-N-aminovalerate passed the significance 
threshold for multiple testing (β = 0.012, SE = 0.002, 
P = 1.52 × 10−8), though the large reduction in the 
strength of association compared to total milk intake sug-
gests trimethyl-N-aminovalerate is not as good a marker of 
total dairy product consumption as for milk intake alone. 
No associations between uridine and other or total dairy 
product intakes passed the significance threshold for mul-
tiple testing. The two lipid metabolites, SM(OH) C14:1 
and PC aa C28:1, were both significantly associated with 
butter intake (SM(OH) C14:1: β = 0.013, SE = 0.002, 
P = 2.67 × 10−11; and PC aa C28:1: β = 0.011, 
SE = 0.002, P = 8.28 × 10−9), and SM(OH) C14:1 was 
also significantly associated with cream intake (β = 0.031, 
SE = 0.007, P = 1.90 × 10−6).
The associations with individual dairy products sug-
gest the lipid metabolites may perform well as markers of 
dairy fat intake. When total milk intake is separated into 
high and low fat (Supplementary Table S2), trimethyl-
N-aminovalerate and uridine are significantly associated 
only with low-fat milk intake (trimethyl-N-aminovalerate: 
β = 0.078, SE = 0.007, P = 1.99 × 10−30; and uridine: 
β = 0.032, SE = 0.007, P = 5.53 × 10−6), while SM(OH) 
C14:1 and PC aa C28:1 are not significantly associated 
with either. When total dairy product intake is separated 
into high- and low-fat dairy products (Supplementary Table 
S2), trimethyl-N-aminovalerate is significantly associated 
only with low-fat dairy intake (β = 0.028, SE = 0.003, 
P = 4.61 × 10−16), while SM(OH) C14:1 and PC aa 
C28:1 are significantly associated with only high-fat dairy 
product intake (SM(OH) C14:1: β = 0.008, SE = 0.001, 
P = 2.23 × 10−9; and PC aa C28:1: β = 0.008, SE = 0.001, 
P = 5.77 × 10−9).
Urinary excretion
We examined urinary metabolites of 236 twins whose 
samples were collected at the same time as blood and con-
firmed a significant association with trimethyl-N-amino-
valerate excretion (β = 0.091, SE = 0.032, P = 0.004) and 
milk intake thus suggesting that urine could also be used to 
evaluate trimethyl-N-aminovalerate levels.
Potential utility of milk‑associated metabolites to act 
as biomarkers
The utility of SM(OH) C14:1, PC aa C28:1, uridine and 
trimethyl-N-aminovalerate (candidate biomarkers), to act 
as markers of milk intake was then assessed by conduct-
ing a binary classification test. Twins consuming the bot-
tom quintile of milk (low intake, mean: 0.7 servings/wk) 
were classed as a negative outcome and top (high intake, 
6.8 servings/wk) quintiles classed as positive outcomes. 
Figure 4 shows the ROC curves for both models as well 
as models for recently confirmed milk fat biomarkers 
pentadecanoic and heptadecanoic acid [25] for compari-
son. The ability of the candidate biomarkers to correctly 
classify twins reporting a high intake of milk per day was 
58 % (sensitivity), whereas 78 % of twins consuming a 
low milk intake were correctly classified (specificity), 
overall 69 % of subjects were correctly classified in this 
model. The AUC for this model was 0.73 (95 % CI 0.66, 
0.79). The AUC for the candidate milk biomarkers was 
significantly greater than milk fat biomarkers (χ2: 21.08, 
P < 0.0001), the AUC for this model was 0.53 (0.46, 
0.60), Supplementary Table S3 contains the results of the 
full analysis.
Fig. 3  Trimethyl-N-aminovalerate versus milk intake for the 10 most 
discordant twin pairs for reported milk intake. Trimethyl-N-amino-
valerate versus milk intake for the 10 most discordant twin pairs for 
reported milk intake. Milk intake (x-axis) versus inverse-normalized 
levels of blood trimethyl-N-aminovalerate (y-axis; unadjusted for age 
or BMI) are shown for the top 10 twin pairs (n = 20) most discordant 
for milk intake. Twin pairs are connected by a line. For 7 out of 10 
twin pairs, a higher intake of milk for Twin 2 corresponds to a higher 
level of trimethyl-N-aminovalerate in the blood (or vice versa)
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Because FFQ data are imprecise due to a number of 
known biases, we attempted to compare the utility of each 
model using genotype to avoid this confounding. Individu-
als who have genotypic lactase non-persistence (lactose 
intolerance) consume on average less milk products than 
those who carry the lactase persistent alleles as they pro-
duce less lactase resulting in GI upset when lactose is con-
sumed in higher amounts. The results of the binary classi-
fication test using lactase genes for each model (candidate 
biomarkers, milk fat biomarkers, reported lactose and milk 
intake) are presented in Table 3, and the ROC curves are 
presented in Fig. 5. The AUC for the candidate biomarkers 
was the largest (0.62[0.55, 0.69]) and significantly differ-
ent than reported milk (χ2: 5.12, P = 0.024) and lactose 
(χ2: 4.53, P = 0.033) intakes though not for milk fat bio-
markers, suggesting the candidate biomarkers capture milk 
intake more accurately than reported intakes. The AUC for 
milk fat biomarkers (0.55[0.48, 0.63]) was not significantly 
different than reported intakes, suggesting it is not an 
improvement over FFQ to measure milk intake. The AUC 
for the candidate biomarkers compared to the milk fat bio-
markers was not statistically different.
Discussion
Using targeted and non-targeted metabolomics approaches, 
we identified four novel metabolites associated with milk 
intake, which we replicated in independent populations: 
SM(OH) C14:1 and PC aa C28:1, uridine and trimethyl-
N-aminovalerate. We have reported a strong and novel 
positive association between circulating levels of trime-
thyl-N-aminovalerate with milk consumption, and we sub-
sequently used the co-twin control method to confirm the 
strength of this association independent of genetics. We 
found these metabolites performed better than FFQ at iden-
tifying genotypic lactase persistent individuals.
The association between reported milk consumption and 
trimethyl-N-aminovalerate is novel and difficult to explain 
due to the lack of literature on this metabolite. Trimethyl-
N-aminovalerate (also known as 5-trimethylaminovaler-
ate, Nδ-Trimethyl-5-aminopentanoate, 5-N-trimethylami-
nopentanoate, or γ-butyrobetaine[GBB]-5) is very likely 
a methylated product of 5-aminovalerate (a lysine or pro-
line degradation product produced by gut microflora [26]). 
Both molecules exhibit structural similarities to carnitine; 
moreover, γ-butyrobetaine hydroxylase (BBOX) catalyzes 
the conversion of gamma butyrobetaine to carnitine [27], 
Fig. 4  ROC curves for candidate biomarkers and milk fat biomarkers 
predictive ability to correctly classify twins reporting low and high 
intakes of milk per week. Receiver operating characteristic curves 
for candidate biomarkers and milk fat biomarkers predictive ability 
to correctly classify twins reporting low and high intakes of milk per 
week. Candidate biomarkers include blood levels of trimethyl-N-ami-
novalerate, uridine, hydroxysphingomyelin C14:1 and diacylphos-
phatidylcholine C28:1. Milk fat biomarkers include blood levels of 
pentadecanoic (C15:0) and heptadecanoic (C17:0) acids. AUC area 
under the receiver operating characteristic curve
Table 3  Results of the binary classification test for the candidate biomarkers, milk fat biomarkers, reported lactose and milk intakes to correctly 
classify lactase persistent and non-persistent twins
The candidate biomarkers (adjusted for covariates), reported milk intake, lactose intake and blood levels of dairy fat biomarkers (adjusted for 
covariates), were each fitted into a logistic regression model to classify lactase persistent individuals (1, positive outcome) versus non (0, nega-
tive outcomes) according to genotype (SNP rs4988235 on the MCM6 gene: CC, n = 63 lactase non-persistent; TT or CT, n = 577 lactase 
persistent). The equality of the receiver operating characteristic area (AUC) for each model was tested against the ROC area for the candidate 
biomarkers. Candidate biomarkers include blood levels of trimethyl-N-aminovalerate, uridine, hydroxysphingomyelin C14:1 and diacylphos-
phatidylcholine C28:1. Milk fat biomarkers include blood levels of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids
AUC area under the receiver operating characteristic curve
Sensitivity (%) Specificity (%) Correctly classified (%) AUC (95 % CI) Versus candidate 
biomarkers
χ2 P
Milk intake 76 36 56 0.53 (0.45, 0.60) 5.12 0.024
Lactose intake 58 50 54 0.53 (0.46, 0.60) 4.53 0.033
Milk fat biomarkers 54 54 54 0.55 (0.48, 0.63) 1.47 0.226
Candidate biomarkers 62 66 64 0.62 (0.55, 0.69)
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which is involved in the generation of metabolic energy 
from long-chain fatty acids. We did not, however, observe a 
positive association between blood carnitine and its metab-
olites and reported milk intake. Thus, these molecules seem 
to be connected through microbial metabolism (that may 
take place in the dairy cow rumen or by milk spoilage bac-
teria) involving BBOX enzymes. Why this association is 
strong with milk intake and not with other dairy products 
(cheese, yoghurt, butter or cream) is unclear, though may 
be related to the different properties of milk, such as the 
higher protein, lactose and water content, non-fermentation 
by beneficial microorganisms and increased susceptibil-
ity to spoilage [27]. Investigations into the metabolome 
of milk have yet to identify trimethyl-N-aminovalerate, 
although this may be related to different metabolomics 
platforms used [28, 29].
We previously reported that circulating trimethyl-N-
aminovalerate (previously misidentified as 3-dehydro-
carnitine) levels are strongly associated with gene vari-
ants on the MARCH8 gene on chromosome 10 (top hit 
SNP = rs2291429, β = 0.02, P = 8.7 × 10−11) [30], which 
was associated with higher milk intake in our population 
(β = 0.165, SE = 0.076, P = 0.031). The MARCH8 or cel-
lular modulator of immune recognition (c-Mir) gene has 
roles in immune regulation [31, 32]. Components of cow’s 
milk protein, caseins, a-lactalbumin and β-lactoglobulin, 
are known allergens [33]. These data provide fur-
ther supportive evidence that milk intake has potential 
immune-mediated effects, though the relationship between 
this gene, trimethyl-N-aminovalerate and milk consump-
tion warrants further investigation.
Despite the limited discourse on the origin of trimethyl-
N-aminovalerate in humans, this metabolite (misidenti-
fied as 3-dehydrocarnitine) has been detected and associ-
ated with health indices in several recent studies using the 
Metabolon platform [34–36]. One small (n = 73) study 
of older overweight adults with limited mobility, sampled 
from a randomized, double-blind, controlled trial evalu-
ating the efficacy of whey protein on resistance exercise-
induced muscle mass gains [37], identified a positive 
association between serum trimethyl-N-aminovalerate and 
abdominal adiposity and intra-muscular adipose tissue in 
the whole group [34]. In the KORA cohort (n = 1762), 
higher serum trimethyl-N-aminovalerate levels were 
observed in subjects using fibrates (n = 5) versus not [35]. 
Use of this metabolite as a milk intake surrogate could pro-
duce other interesting epidemiological findings.
Uridine is a nucleotide base involved in pyrimidine 
metabolism. Uridine is directly involved in the conversion 
of galactose to glucose, though it is not clear that this pro-
cess could raise human blood uridine levels. Bovine milk is 
abundant in uridine metabolites, with uridine 5′monophos-
phate (5′UMP) accounting for between 86 and 90 % of all 
nucleotides [38]. Though studies are limited for the bio-
availability of food uridine metabolites in humans, oral 
feeding of 5′UMP has shown to rapidly raise serum uridine 
in gerbils [39] and is also the predominant uridine metabo-
lite in human breast milk and infant formula. Interestingly, 
higher blood uridine levels were associated with lower 
carotid–femoral pulse-wave velocity, a measure of arte-
rial stiffness, in 1797 twins from the TwinsUK cohort [40]. 
Moreover, expression levels in fat of the purinergic recep-
tor P2Y gene were associated with circulating uridine in 
TwinsUK, which modulates endothelial nitric oxide syn-
thase phosphorylation [41].
Total circulating phospholipid myristic acid (14:0) has 
recently been used as a biomarker of dairy fat intake on 
CVD risk and incident coronary heart disease in a multi-
ethnic US adult cohort (n = 2837), although no associa-
tions were found [42]. We identified positive associations 
between milk consumption and SM(OH) C14:1 and PC aa 
C28:1, and these phospholipids are typically composed of 
myristoleic and myristic (only for PC aa C28:1) acid moi-
eties that are found in characteristically high concentra-
tions in milk fat as structures in the milk fat globule mem-
brane [43]. These reflect findings from the EPIC-Potsdam 
subcohort (n = 2380) where a pattern with high intake of 
butter and low intake of margarine accounted for 8 % of 
the variation in circulating levels of SM(OH) C14:1 [44]. 
These markers may be more useful for measuring the 
intake of higher fat milk products and would not adequate 
Fig. 5  ROC curves for candidate and milk fat biomarkers, reported 
lactose and milk intake predictive ability to correctly classify twins 
with genotypic lactase persistence and non-persistence. Receiver 
operating characteristic curves for candidate biomarkers, milk fat 
biomarkers, reported lactose and milk intake predictive ability to 
correctly classify twins with genotypic lactase persistence and non-
persistence. Candidate biomarkers include blood levels of trimethyl-
N-aminovalerate, uridine, hydroxysphingomyelin C14:1 and dia-
cylphosphatidylcholine C28:1. Milk fat biomarkers include blood 
levels of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids. 
AUC area under the receiver operating characteristic curve
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to measure skimmed milk intake for instance; however, the 
inclusion of these metabolites did improve the predictive 
performance of our models.
This study being cross-sectional has some limitations. 
Questionnaires were used to assess milk consumption for 
all groups, which have been plagued by issues of partici-
pant reporting [45], though this allowed direct comparisons 
across the populations used. Validation of the EPIC-Nor-
folk FFQ used for TwinsUK against 7-day diet diaries dem-
onstrated a tendency to over-report milk intake (350 g per 
day for FFQ, 200 g per day according to diary) [46], mak-
ing precise quantification of milk intake unlikely. However, 
intakes derived from FFQ were found to rank participants 
in extremes well [46]. We attempted to overcome this issue 
by applying a novel approach using genotype to evaluate 
our models predictive performance against confirmed bio-
markers of milk fat intake and reported lactose and milk 
intakes. Future studies should employ interventions to con-
firm our findings, and the discovery of other metabolites 
could further improve the predictive ability. Moreover, the 
origin of the association between milk intake and trime-
thyl-N-aminovalerate requires further investigation. In par-
ticular, metabolomic profiling of milk should be undertaken 
in future studies. Our study has multiple strengths. Our dis-
covery population had a large sample size with the main 
results replicated in two independent populations from 
different countries and cultures of both sexes, suggesting 
generalizability. We were able to use discordant MZ twins, 
controlled for confounders of age, sex, the primary DNA 
sequence, and a shared early environment, to confirm the 
strength of our top association.
Conclusions
With the use of high-throughput multi-platform metabo-
lomics, we have identified and successfully replicated in 
independent populations four novel metabolites associated 
with milk consumption. Moreover, our evaluation of the 
ability of these metabolites to predict genotypic lactase per-
sistence versus non-persistence suggests they perform bet-
ter than milk fat biomarkers or reported lactose and milk 
intake as markers of milk intake. This study demonstrates 
the advantages of metabolomics in nutritional epidemiol-
ogy, and these novel metabolites have the potential to act as 
objective biomarkers to strengthen epidemiological studies 
determining the impact of milk intake on health.
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